Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Divalproex sodium is a drug, or a medicine used to treat certain types of epilepsy. This drug is an anticonvulsant which works in the brain tissue to stop seizures and a compound of sodium valproate and valproic acid. Moreover, it is also used for the treatment of manic phase of bipolar disorder (manic-depressive illness) and helps prevent migraine headaches.
The global market is estimated and forecasted in terms of revenue (USD million) generated by the divalproex sodium market. The divalproex sodium market has a developing potential owing to increasing rate of bipolar disorders and rising concern of the people towards various diseases. Moreover, increasing prevalence of lifestyle diseases and increasing healthcare expenditure of the people in developed and developing countries is propelling the growth of the market. However, the prominent factor restraining the growth of the global divalproex sodium market are unstable healthcare reforms and risk associated with the consumption of divalproex sodium market.
The global divalproex sodium market is segmented by dosage type, application, distribution channel and geography.
Based on dosage type, the market is categorised into, capsule, tablet and syrup. The tablets segment dominated the divalproex sodium market in 2017 and is expected to maintain its dominance over the projected period. The high growth in the tablet segment can be primarily attributed to increasing patient population and rising awareness about epilepsy and manic-depressive Illness disorders globally.
Likewise, by application, the divalproex sodium market is segmented into, epilepsy, manic depressive illness and migraine headaches. The epilepsy segment leads the market and is expected to register for highest CAGR during the forecast period as divalproex sodium is mostly used for the treatment of epilepsy and Increasing prevalence of epilepsy disorders around the globe.
Based on distribution channel the global divalproex sodium market is segmented into hospital pharmacies, retail pharmacies and online Pharmacies. Among these, the hospital segment is accounted for largest share of the global divalproex sodium market in 2017. This large share is mainly attributed to factors such as increasing number of patients with epilepsy and manic-depressive illness disorders in the hospital.
By geography, the global divalproex sodium market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and rest of the world. Rest of the world includes Middle East & Africa and Latin America. North America is expected to be the fastest-growing region during the prediction period, owing to the factors such well-established healthcare infrastructure in the region, increasing government initiatives and high expenditure on research & development.
Some of the key participants in the divalproex sodium market are Zydus Pharmaceuticals, Inc, AbbVie Inc, Mylan N.V, Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd, LUPIN, Orchid Chemicals & Pharamaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Abbott, etc. Furthermore, expansions, mergers and partnership are the strategies implemented by key market players to expand their R&D competences and geographic presence in the global market.
Divalproex sodium is an anticonvulsant (antiseizure) drug. It is also used to treat mania and to help prevent migraine headaches. It is sold under multiple brand names in the United States, including Depacon, Depakene, Depakote, and Depakote sprinkle. Divalproex sodium is also used to treat the manic phase of bipolar disorder in adults, and to prevent migraine headache in adults. The global divalproex sodium market is segmented into, dosage type, application, distribution channel and geography. Based on dosage type, the market is categorised into, capsule, tablet and syrup. Likewise, by application, the divalproex sodium market is segmented into, epilepsy, manic depressive illness and migraine headaches. Based on distribution channel the global divalproex sodium market is segmented into hospital pharmacies, retail pharmacies and online Pharmacies. By geography, the global divalproex sodium market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and rest of the world. Rest of the world includes Middle East & Africa and Latin America. North America is expected to be the fastest-growing region during the prediction period, owing to the factors such well-established healthcare infrastructure in the region, increasing government initiatives and high expenditure on research & development. Some of the key participants in the divalproex sodium market are Zydus Pharmaceuticals, Inc, AbbVie Inc, Mylan N.V, Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd, LUPIN, Orchid Chemicals & Pharamaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Abbott, etc. Furthermore, expansions, mergers and partnership are the strategies implemented by key market players to expand their R&D competences and geographic presence in the global market.
Why to buy this report:
